Vaximm has successfully completed multiple clinical trials demonstrating the efficacy of its lead product candidate, leading to partnerships with major pharmaceutical companies.
Founders
Dr. Rainer H. Schmid, Dr. Michael H. Schmitt
Company Description
Vaximm is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company leverages its proprietary platform to create therapeutic vaccines that stimulate the immune system to target and destroy cancer cells.